Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA4 | P22748 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | TMEM97 | Q5BJF2 | 5/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL186313 | 0.85 | CA12 (0.56) | CA12CA1CA2CA4CA9 | |
| SCHEMBL187219 | 0.84 | CA1 (0.55) | CA12CA1CA2CA4CA9 | |
| SCHEMBL3642316 | 0.84 | CA12 (0.58) | CA12CA1CA2CA4CA9 | |
| SCHEMBL12861014 | 0.84 | MAOB (0.59) | CA12CA1CA2CA4CA9 | |
| SCHEMBL4128246 | 0.80 | CA2 (0.50) | CA12CA1CA2CA4CA9 | |
| SCHEMBL17369722 | 0.80 | CA12 (0.51) | CA12CA1CA2CA4CA9 | |
| SCHEMBL5155604 | 0.79 | CA12 (0.49) | CA12CA1CA2CA4CA9 | |
| SCHEMBL2958012 | 0.78 | CA12 (0.64) | CA12CA1CA2CA4CA9 | |
| SCHEMBL220304 | 0.78 | CA2 (0.53) | CA12CA1CA2CA4CA9 | |
| SCHEMBL12647546 | 0.77 | CA12 (0.71) | CA12CA1CA2CA4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1395544-B1 | METHODS OF MAKING 21- 4'-(NITROOXYALKYL) BENZOATE CORTICOSTEROID DERIVATIVES AND INTERMEDIATES USEFUL IN THE SYNTHESIS THEREOF | NICOX SA (FR) | 2012-01-04 | — | — | EP | disclosed |
| EP-1395544-A4 | METHODS OF MAKING 21- 4'-(NITROOXYALKYL) BENZOATE CORTICOSTEROID DERIVATIVES AND INTERMEDIATES USEFUL IN THE SYNTHESIS THEREOF | NICOX SA (FR) | 2009-05-27 | — | — | EP | disclosed |
| EP-1395544-A1 | METHODS OF MAKING 21- 4'-(NITROOXYALKYL) BENZOATE] CORTICOSTEROID DERIVATIVES AND INTERMEDIATES USEFUL IN THE SYNTHESIS THEREOF | Scynexis Chemistry and Automation, Inc. (US) | 2004-03-10 | — | — | EP | disclosed |
| US-6696592-B2 | FORMING REDUCED SIDE EFFECTS DERIVATIVE | NICOX-S.A. (FR) | 2004-02-24 | — | — | US | disclosed |
| US-20030153545-A1 | Methods of making 21-[4'-(nitrooxyalkyl)benzoate] corticosteroid derivatives and intermediates useful in the synthesis thereof | NICOX S.A. (FR) | 2003-08-14 | — | — | US | disclosed |
| WO-2002094942-A1 | METHOD OF PURIFYING POLYCYCLIC DYES | OPTIVA, INC. (US) | 2002-11-28 | — | — | WO | disclosed |
| WO-2002094758-A1 | METHODS OF MAKING 21-[4'-(NITROOXYALKYL) BENZOATE] CORTICOSTEROID DERIVATIVES AND INTERMEDIATES USEFUL IN THE SYNTHESIS THEREOF | NICOX S. A. (FR) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153545-A1 | Methods of making 21-[4'-(nitrooxyalkyl)benzoate] corticosteroid derivatives and intermediates useful in the synthesis thereof | CYP11B1, CYP17A1, CYP21A2 | CA12 1470/4885CA1 1823/4885CA2 2168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.